Media coverage about Masimo Corporation (NASDAQ:MASI) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Masimo Corporation earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.5830118034585 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- Analysts Expect Masimo Corporation (MASI) Will Post Quarterly Sales of $201.63 Million (americanbankingnews.com)
- Latin America Capnography Equipment Market to Register a CAGR Growth of 17.5% Throughout 2014-2021 (sbwire.com)
- Primary Ciliary Dyskinesia Market Estimated For a Spurting Accrual by 2023 With A Whooping CAGR of 6.7% (abnewswire.com)
- ETFs with exposure to Masimo Corp. : November 17, 2017 (finance.yahoo.com)
- mHealth Monitoring And Diagnostic Medical Devices Market Set to Witness an Uptick during 2013-2019 (reports.pr-inside.com)
A number of equities research analysts have weighed in on MASI shares. Stifel Nicolaus reiterated a “buy” rating and set a $108.00 target price (up from $105.00) on shares of Masimo Corporation in a research note on Thursday, August 3rd. Zacks Investment Research raised shares of Masimo Corporation from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Thursday, November 2nd. BTIG Research raised shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Monday, August 14th. Finally, BidaskClub downgraded shares of Masimo Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $97.17.
Masimo Corporation (NASDAQ:MASI) last issued its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.17. The company had revenue of $193.69 million during the quarter, compared to the consensus estimate of $189.01 million. Masimo Corporation had a net margin of 45.83% and a return on equity of 22.17%. Masimo Corporation’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.52 EPS. equities research analysts expect that Masimo Corporation will post 2.95 earnings per share for the current year.
In other Masimo Corporation news, Director Steven Barker sold 10,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Yongsam Lee sold 13,976 shares of the stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $89.43, for a total transaction of $1,249,873.68. Following the transaction, the executive vice president now directly owns 74,000 shares of the company’s stock, valued at approximately $6,617,820. The disclosure for this sale can be found here. Insiders sold a total of 28,976 shares of company stock valued at $2,599,324 in the last ninety days. 13.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-masimo-corporation-masi-share-price.html.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.